据Frost和Sullivan报告,预计免疫治疗制剂市场销售额将从1986年的7977万美元增长至1990年的15亿美元.当前主要是药品,销售量占86.7%,到1990年将下降至63.3%,单克隆抗体和淋巴细胞因子的比重将增长.目前用于免疫治疗的药品是免疫抑制剂,每一种免疫抑制药物对某一类型的免疫应答有专一抑制作用.免疫治疗中两个有希望的方面是:单克隆抗体的应用和用淋巴细胞因子作免疫调节剂.尽管这两类制剂尚未进入市场,但现已可见它们将可 According to reports from Frost and Sullivan, the sales volume of immunotherapeutic preparations is expected to increase from $79.77 million in 1986 to $1.5 billion in 1990. Currently, it is mainly pharmaceuticals, which account for 86.7% of sales, and will drop to 63.3% by 1990. The proportion of monoclonal antibodies and lymphocyte factors will increase. The current drugs used for immunotherapy are immunosuppressive drugs. Each type of immunosuppressive drug has a specific inhibitory effect on a certain type of immune response. There are two hopeful aspects in immunotherapy. The aspects are: the use of monoclonal antibodies and the use of lymphocyte factors as immunomodulators. Although these two types of agents have not yet entered the market, it is now apparent that they will